靶向泛素激活酶诱导B细胞淋巴瘤细胞发生内质网应激介导的凋亡
研究显示,泛素激活酶抑制剂TAK-243可破坏弥漫大B细胞淋巴瘤(DLBCL)细胞的泛素信号与整体蛋白泛素化,诱导内质网应激和未折叠蛋白反应,引发凋亡与细胞周期阻滞;MYC高表达增强敏感性,体内实验抑制移植瘤生长,原代患者DLBCL细胞也显示敏感。
要点
- TAK-243破坏DLBCL细胞泛素信号,诱导内质网应激与未折叠蛋白反应。
- TAK-243诱导凋亡不依赖细胞来源,MYC表达增强敏感性。
- TAK-243在DLBCL细胞中较硼替佐米更有效,体内抑制移植瘤生长。
核心结论
- 靶向泛素激活酶可能成为非霍奇金淋巴瘤(NHL)有前景的新治疗策略。
研究设计与样本
- 体外研究:使用DLBCL细胞系、工程化MYC表达或敲低细胞、原代患者来源DLBCL细胞及异种移植瘤模型评估TAK-243。
主要发现
- TAK-243破坏DLBCL细胞所有泛素信号和整体蛋白泛素化,诱导内质网应激和未折叠蛋白反应。
- 激活PKR样内质网激酶和真核翻译起始因子2α磷酸化导致促凋亡分子C/EBP同源蛋白上调,在多个DLBCL细胞系中引起细胞死亡,不依赖细胞来源。
- 靶向泛素激活酶导致复制许可因子Cdt1积累,引发DNA再复制、检查点激活和细胞周期阻滞。
- MYC癌蛋白使DLBCL细胞对泛素激活酶抑制敏感:工程化MYC表达增强TAK-243诱导的凋亡,而遗传性MYC敲低则保护细胞。
- 与硼替佐米相比,泛素激活酶抑制在DLBCL细胞系中增强内质网应激和未折叠蛋白反应并提高效力;体内TAK-243治疗限制异种移植DLBCL肿瘤生长,伴随细胞增殖减少和凋亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), novel approaches to target the UPS are needed. Here, we show that TAK-243, the first small-molecule inhibitor of the ubiquitin activating enzyme (UAE) to enter clinical development, disrupts all ubiquitin signaling and global protein ubiquitination in diffuse large B-cell lymphoma (DLBCL) cells, thereby inducing endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Activation of the ER stress response protein kinase R (PKR)-like ER kinase and phosphorylation of eukaryotic translation initiator factor 2α led to upregulation of the proapoptotic molecule C/EBP homologous protein and cell death across a panel of DLBCL cell lines independent of cell of origin. Concurrently, targeting UAE led to accumulation of Cdt1, a replication licensing factor, leading to DNA rereplication, checkpoint activation, and cell cycle arrest. MYC oncoprotein sensitized DLBCL cells to UAE inhibition; engineered expression of MYC enhanced while genetic MYC knockdown protected from TAK-243-induced apoptosis. UAE inhibition demonstrated enhanced ER stress and UPR and increased potency compared with bortezomib in DLBCL cell lines. In vivo treatment with TAK-243 restricted the growth of xenografted DLBCL tumors, accompanied by reduced cell proliferation and apoptosis. Finally, primary patient-derived DLBCL cells, including those expressing aberrant MYC, demonstrated susceptibility to UAE inhibition. In sum, targeting UAE may hold promise as a novel therapeutic approach in NHL.
引用
- Best S, Hashiguchi T, Kittai A, et al. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Adv. 2019. PMID: 30617217. doi:10.1182/bloodadvances.2018026880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。